|
Characteristics
|
Frequency
|
P value
|
|---|
|
Standard dose
|
Dose escalation
|
|---|
|
Total number
|
10
|
15
| |
|
Female: male
|
5:5
|
8:7
| |
|
Age (year)
|
63.0 (34.0–78.0)
|
55.0 (19.0–81.0)
|
0.183
|
|
Phase, CP: AP: BP
|
7:2:1
|
15:0:0
| |
|
Reason of taking bosutinib, TKI-R: TKI-Int: de novo CML
|
4:5:1
|
9:6:0
| |
|
Body weight (kg)
|
59.9 (40.8–69.1)
|
53.0 (44.1–86.3)
|
0.889
|
|
Laboratory test values
|
|
White blood cell (*103/mm3)
|
8.5 (3.6–190.7)
|
6.1 (1.3–13.8)
|
0.332
|
|
Hemoglobin (g/dL)
|
10.3 (8.2–14.2)
|
12.1 (8.3–14.8)
|
0.052
|
|
Platelet (*104/mm3)
|
29.5 (12.1–326.0)
|
19.4 (12.8–162.0)
|
0.120
|
|
Aspartate transaminase (IU/L)
|
23.0 (14.0–56.0)
|
24.0 (10.0–47.0)
|
0.487
|
|
Alanine transaminase (IU/L)
|
17.5 (9.0–65.0)
|
23.0 (7.0–34.0)
|
0.232
|
|
Serum albumin (g/dL)
|
4.1 (3.7–4.3)
|
4.2 (3.0–5.2)
|
0.179
|
|
Total bilirubin (mg/dL)
|
0.6 (0.2–0.9)
|
0.6 (0.3–2.7)
|
0.557
|
|
Serum creatinine (mg/dL)
|
0.8 (0.5–0.9)
|
0.7 (0.4–1.7)
|
0.803
|
|
Lipase (IU/L)
|
21.5 (5.0–75.0)
|
18.0 (6.0–38.0)
|
0.781
|
- Data presented as number or median (minimum–maximum)
- TKI tyrosine kinase inhibitor, R resistance, Int intolerance
